Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | CDYL2 | Q8N8U2 | 4/20 | 0.41 |
| ▸ | CDYL | Q9Y232 | 4/20 | 0.41 |
| ▸ | CBX7 | O95931 | 3/20 | 0.41 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2996646 | 0.92 | GAA (0.42) | POLBGAATSHRCDYL2CDYL | |
| SCHEMBL2997041 | 0.88 | MAPK1 (0.44) | POLBGAATACR1CYP3A4 | |
| SCHEMBL5227968 | 0.88 | HRH3 (0.41) | POLBGAATSHRTACR1CDYL2 | |
| SCHEMBL2996475 | 0.86 | POLB (0.47) | POLBGAATSHRTACR1CDYL2 | |
| SCHEMBL5733273 | 0.86 | ACHE (0.47) | POLBGAATSHRCDYL2CDYL | |
| Hydrochloric Acid SCHEMBL423770 | 0.85 | ACHE (0.47) | POLBGAATSHRCDYL2CDYL | |
| SCHEMBL4878071 | 0.82 | TP53 (0.35) | POLBGAATSHRCDYL2CDYL | |
| SCHEMBL4877285 | 0.82 | MAPT (0.36) | POLBGAATSHRCDYL2CDYL | |
| SCHEMBL2982864 | 0.81 | SLC8A1 (0.34) | TACR1 | |
| SCHEMBL2987937 | 0.81 | CNR1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036443-A1 | Thienopyrroles as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI (IT) | 2009-02-05 | — | — | US | claimed |
| EP-1664059-B1 | THIENOPYRROLES AS ANTIVIRAL AGENTS | ANGELETTI P IST RICHERCHE BIO (IT) | 2007-09-12 | — | — | EP | claimed |
| JP-2007505091-A | — | — | 2007-03-08 | — | — | JP | claimed |
| EP-1664059-A1 | THIENOPYRROLES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2006-06-07 | — | — | EP | claimed |
| WO-2005023819-A9 | THIENOPYRROLES AS ANTIVIRAL AGENTS | ANGELETTI P IST RICHERCHE BIO (IT) | 2006-03-23 | — | — | WO | claimed |
| WO-2005023819-A1 | THIENOPYRROLES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2005-03-17 | — | — | WO | claimed |
| US-7781431-B2 | Thienopyrroles as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2010-08-24 | — | — | US | disclosed |
| US-7781431-B2 | Thienopyrroles as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2010-08-24 | — | — | US | disclosed |
| US-7781431-B2 | Thienopyrroles as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2010-08-24 | — | — | US | disclosed |
| US-20090036443-A1 | Thienopyrroles as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI (IT) | 2009-02-05 | — | — | US | disclosed |
| US-20090036443-A1 | Thienopyrroles as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI (IT) | 2009-02-05 | — | — | US | disclosed |
| US-20090036443-A1 | Thienopyrroles as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI (IT) | 2009-02-05 | — | — | US | disclosed |
| EP-1664059-B1 | THIENOPYRROLES AS ANTIVIRAL AGENTS | ANGELETTI P IST RICHERCHE BIO (IT) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036443-A1 | Thienopyrroles as antiviral agents | ZC3HAV1, XDH, TPMT | POLB 2398/4885GAA 1769/4885TSHR 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.